Sevirumab: Difference between revisions

Revision as of 22:31, 13 November 2011 editThe chemistds (talk \| contribs)Extended confirmed users5,761 edits No ChemSpider ID for this record← Previous edit		Revision as of 22:42, 13 November 2011 edit undoCheMoBot (talk \| contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_...Next edit →
Line 1:		Line 1:
	{{Drugbox		{{Drugbox
			\| Verifiedfields = changed
	\| verifiedrevid = 447741609		\| verifiedrevid = 447741609

Line 28:		Line 29:

	<!--Identifiers-->		<!--Identifiers-->
			\| ChemSpiderID_Ref = {{chemspidercite\|changed\|chemspider}}
	\| ChemSpiderID = NA		\| ChemSpiderID = NA
	\| CAS_number_Ref = {{cascite\|correct\|??}}		\| CAS_number_Ref = {{cascite\|correct\|??}}

Revision as of 22:42, 13 November 2011

Pharmaceutical compound

Sevirumab (MSL-109) is a human monoclonal antibody for the treatment of infections with cytomegalovirus in patients with AIDS.

Borucki, MJ; Spritzler, J; Asmuth, DM; Gnann, J; Hirsch, MS; Nokta, M; Aweeka, F; Nadler, PI; Sattler, F (2004). "A phase II, double-masked, randomized, placebo-controlled evaluation of a human monoclonal anti-Cytomegalovirus antibody (MSL-109) in combination with standard therapy versus standard therapy alone in the treatment of AIDS patients with Cytomegalovirus retinitis". Antiviral research. 64 (2): 103–11. doi:10.1016/j.antiviral.2004.06.012. PMID 15498605.
ClinicalTrials.gov

Human	Efungumab

Human	Ansuvimab Atoltivimab (+maftivimab/odesivimab) Avdoralimab Bamlanivimab (+etesevimab) Bebtelovimab Casirivimab (+imdevimab) Cilgavimab (+tixagevimab) Diridavumab Etesevimab Exbivirumab Foravirumab Imdevimab (+casirivimab) Libivirumab Maftivimab Nirsevimab Odesivimab Pemivibart Rafivirumab Regavirumab Regdanvimab Sevirumab Sipavibart Sotrovimab Suptavumab Tixagevimab (+cilgavimab) Tuvirumab
Chimeric	Cosfroviximab Larcaviximab Porgaviximab Vilobelimab
Humanized	Felvizumab Lenvervimab Motavizumab Palivizumab Suvizumab

Human	Nebacumab Panobacumab Raxibacumab
Mouse	Edobacomab
Chimeric	Pagibaximab
Humanized	Tefibazumab

Human	Actoxumab Bezlotoxumab Suvratoxumab
Chimeric	Obiltoxaximab
Humanized	Urtoxazumab

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.